SCHEMBL411110

SCHEMBL411110

O=C(O)CCC(C(=O)O)N1C(=O)c2ccccc2C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 1.00
POLB P06746 4/20 1.00
KDM4E B2RXH2 2/20 1.00
HPGD P15428 2/20 1.00
MAPK1 P28482 2/20 1.00
HSD17B10 Q99714 2/20 1.00
TP53 P04637 1/20 1.00
GLA P06280 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
ALOX12 P18054 1/20 1.00
NFKB1 P19838 1/20 1.00
APEX1 P27695 1/20 1.00
GAA P10253 2/20 0.64
KMT2A Q03164 3/20 0.57
MEN1 O00255 1/20 0.57
L3MBTL1 Q9Y468 2/20 0.53
HIF1A Q16665 1/20 0.52
MAPT P10636 1/20 0.52
ALOX15 P16050 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7285516 1.00 ALDH1A1 (1.00) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL29763164 1.00 ALDH1A1 (1.00) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL411173 1.00 ALDH1A1 (1.00) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL14991107 1.00 ALDH1A1 (1.00) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL441970 1.00 ALDH1A1 (1.00) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL31710840 0.90 ALDH1A1 (0.82) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL9741723 0.90 ALDH1A1 (0.82) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL2172873 0.90 ALDH1A1 (0.81) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL6896852 0.88 ALDH1A1 (0.79) ALDH1A1POLBKDM4EHPGDMAPK1
SCHEMBL6896845 0.88 ALDH1A1 (0.79) ALDH1A1POLBKDM4EHPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118530786-A Film stripping liquid suitable for flexible circuit board and preparation method thereof 深圳市天熙科技开发有限公司 2024-08-23 CN claimed
CN-110643670-A Method for preparing D-glutamine by chemical enzyme method 湖北新生源生物工程有限公司 2020-01-03 CN claimed
US-7723425-B2 Pigment compositions with modified ATRP copolymer dispersants CIBA SPECIALTY CHEMICALS CORPORATION (US) 2010-05-25 US claimed
EP-1920773-A1 Compositions for inhibition of anglogenesis The Children's Medical Center Corporation (US) 2008-05-14 EP claimed
EP-1586322-A2 Compositions for inhibition of anglogenesis The Children's Medical Center Corporation (US) 2005-10-19 EP claimed
US-20040248820-A1 Methods and compositions for inhibition of angiogenesis D AMATO ROBERT J (US) 2004-12-09 US claimed
US-20030191098-A1 Methods and compositions for inhibition of angiogenesis D AMATO ROBERT J (US) 2003-10-09 US claimed
JP-2002513391-A 2002-05-08 JP claimed
EP-0963200-A2 METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS The Children's Medical Center Corporation (US) 1999-12-15 EP claimed
WO-1998019649-A2 METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 1998-05-14 WO claimed
EP-0688211-A4 METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS CHILDRENS MEDICAL CENTER (US) 1997-05-21 EP claimed
US-5593990-A Methods and compositions for inhibition of angiogenesis THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 1997-01-14 US claimed
EP-0688211-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS The Children's Medical Center Corporation (US) 1995-12-27 EP claimed
WO-1994020085-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 1994-09-15 WO claimed
EP-4649963-A2 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2025-11-19 EP disclosed
EP-3131588-B1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2025-11-05 EP disclosed
EP-4509184-A2 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas Operations, Inc. (US) 2025-02-19 EP disclosed
US-4687817-A REACTION WITH PHTHALOYLAMINO ACID OR DERIVATIVE, HYDRAZINE NITTO BOSEKI CO. LTD. (JP) 1987-08-18 US disclosed
US-4604451-A Novel functionalized resin derived from polyallylamine NITTO BOSEKI CO., LTD. (JP) 1986-08-05 US disclosed
EP-0154742-A2 Novel functionalized resin derived from polyallylamine NITTO BOSEKI CO., LTD. (JP) 1985-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248820-A1 Methods and compositions for inhibition of angiogenesis PGF, PTGS1, PTGIS ALDH1A1 436/4885POLB 2940/4885KDM4E 2121/4885
US-20030191098-A1 Methods and compositions for inhibition of angiogenesis PGF, PTGS1, PTGIS ALDH1A1 436/4885POLB 2940/4885KDM4E 2121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.